pf-05231023 has been researched along with Body-Weight* in 2 studies
1 trial(s) available for pf-05231023 and Body-Weight
Article | Year |
---|---|
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
FGF21 plays a central role in energy, lipid, and glucose homeostasis. To characterize the pharmacologic effects of FGF21, we administered a long-acting FGF21 analog, PF-05231023, to obese cynomolgus monkeys. PF-05231023 caused a marked decrease in food intake that led to reduced body weight. To assess the effects of PF-05231023 in humans, we conducted a placebo-controlled, multiple ascending-dose study in overweight/obese subjects with type 2 diabetes. PF-05231023 treatment resulted in a significant decrease in body weight, improved plasma lipoprotein profile, and increased adiponectin levels. Importantly, there were no significant effects of PF-05231023 on glycemic control. PF-05231023 treatment led to dose-dependent changes in multiple markers of bone formation and resorption and elevated insulin-like growth factor 1. The favorable effects of PF-05231023 on body weight support further evaluation of this molecule for the treatment of obesity. Longer studies are needed to assess potential direct effects of FGF21 on bone in humans. Topics: Adolescent; Adult; Aged; Animals; Anti-Obesity Agents; Antibodies, Monoclonal, Humanized; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Female; Fibroblast Growth Factors; Gene Expression; Humans; Insulin; Lipid Metabolism; Macaca fascicularis; Male; Middle Aged; Obesity; Subcutaneous Fat; Weight Loss; Young Adult | 2016 |
1 other study(ies) available for pf-05231023 and Body-Weight
Article | Year |
---|---|
PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates.
PF-05231023, a long-acting FGF21 analogue, is a promising potential pharmacotherapy for the treatment of obesity and associated comorbidities. Previous studies have shown the potential of FGF21 and FGF21-like compounds to decrease body weight in mice, non-human primates, and humans; the precise mechanisms of action remain unclear. In particular, there have been conflicting reports on the degree to which FGF21-induced weight loss in non-human primates is attributable to a decrease in food intake versus an increase in energy expenditure. Here, we present a semi-mechanistic mathematical model of energy balance and body composition developed from similar work in mice. This model links PF-05231023 administration and washout to changes in food intake, which in turn drives changes in body weight. The model is calibrated to and compared with recently published data from cynomolgus macaques treated with PF-05231023, demonstrating its accuracy in describing pharmacotherapy-induced weight loss in these animals. The results are consistent with the hypothesis that PF-05231023 decreases body weight in cynomolgus macaques solely by a reduction in food intake, with no direct effect on energy expenditure. Topics: Animals; Anti-Obesity Agents; Antibodies, Monoclonal, Humanized; Body Weight; Dose-Response Relationship, Drug; Eating; Energy Metabolism; Fibroblast Growth Factors; Injections, Intravenous; Macaca fascicularis; Male; Models, Biological; Obesity | 2016 |